Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

419
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
419
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

444
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
444
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

358
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
358
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

792
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
792
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

520
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
520

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteomics risk scores and mortality in heart failure: Generalizability across populations.

PloS one·2026
Same author

Effect of Omega-3 Fatty Acid Intake on Circulating Biomarkers of Atrial Fibrillation-Related Pathways in the PREDIMED-Plus Study.

Nutrients·2026
Same author

Personal Care Products and Incident Hypertension: Prospective Cohort Study of U.S. Women.

medRxiv : the preprint server for health sciences·2026
Same author

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Research square·2026
Same author

Genotype epigenome phenotype integration reveals peripheral immune contributions to type I bipolar disorder.

Nature communications·2026
Same author

Mitral Annular Disjunction: Separating the Wheat from the Chaff.

Arrhythmia & electrophysiology review·2026

Related Experiment Video

Updated: Feb 26, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K

Multimorbidity in Atrial Fibrillation: Impact on Outcomes.

Sheila M Manemann1, Alvaro Alonso2, Peter A Noseworthy3

  • 1Department of Quantitative Health Sciences Mayo Clinic Rochester MN USA.

Journal of the American Heart Association
|February 24, 2026
PubMed
Summary
This summary is machine-generated.

The number and type of comorbidities significantly impact atrial fibrillation (AF) patient outcomes, with effects varying by age. Cardiometabolic, somatic, and mental health conditions all play a role in predicting adverse events.

Keywords:
atrial fibrillationchronic conditionsmultimorbidityoutcomes

More Related Videos

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

2.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Related Experiment Videos

Last Updated: Feb 26, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

2.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Area of Science:

  • Cardiology
  • Geriatrics
  • Public Health

Background:

  • Multimorbidity is prevalent in patients diagnosed with atrial fibrillation (AF).
  • The specific influence of the quantity and nature of comorbid conditions on patient outcomes in AF remains unclear.

Purpose of the Study:

  • To investigate the association between the number and types of chronic conditions and adverse outcomes in patients with new-onset atrial fibrillation.
  • To examine how these associations differ across various age groups.

Main Methods:

  • A cohort study was conducted using data from new-onset atrial fibrillation patients (2013-2017).
  • Eighteen chronic conditions were categorized into cardiometabolic, other somatic, and mental health groups.
  • Cox regression analysis was employed to assess the relationship between condition types and outcomes (death, stroke, heart failure), stratified by age.

Main Results:

  • The study included 16,509 AF patients (mean age 74 years; 43% women).
  • Higher numbers of cardiometabolic conditions increased 90-day mortality risk only in those aged ≥85 years.
  • Associations between comorbidities and outcomes were generally strongest in younger age groups (<65 years) and diminished with advancing age, particularly for somatic conditions.

Conclusions:

  • Cardiometabolic, other somatic, and mental health conditions are significant predictors of outcomes in atrial fibrillation patients.
  • The impact of these comorbidities on outcomes is age-dependent and warrants consideration in clinical management.
  • Comprehensive assessment of comorbidities is crucial for optimizing care in AF patients.